Display Settings:

Format

Send to:

Choose Destination
    Vaccine. 2008 Dec 9;26(52):6883-93. Epub 2008 Oct 20.

    Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy.

    Source

    Pediatrics and Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, USA. thomas.greenough@umassmed.edu

    Abstract

    A trial to evaluate the safety and immunogenicity of recombinant modified vaccinia Ankara (MVA) and fowlpox (FP) vectors expressing multiple HIV-1 proteins was conducted in twenty HIV-1 infected youth with suppressed viral replication on HAART. The MVA and FP-based multigene HIV-1 vaccines were safe and well tolerated. Increased frequencies of HIV-1 specific CD4+ proliferative responses and cytokine secreting cells were detected following immunization. Increased frequencies and breadth of HIV-1 specific CD8 T-cell responses were also detected. Plasma HIV-1-specific antibody levels and neutralizing activity were unchanged following vaccination. Poxvirus-based vaccines may merit further study in therapeutic vaccine protocols.

    PMID:
    18940219
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2845914
    Free PMC Article

    Images from this publication.See all images (5) Free text

    Fig. 1
    Fig. 3
    Fig. 5
    Fig. 2
    Fig. 4

      Supplemental Content

      Icon for Elsevier Science Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk